CorMedix (CRMD) Tops Q3 EPS by 6c

CorMedix (NASDAQ: CRMD) reported Q3 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $11.5 million versus the consensus estimate of $10.35 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• Jefferies says used farm equipment pricing stays under pressure